Yahoo Web Search

Search results

1. • 

     KRAS inhibitors: The next frontier beckons

     Pharmaceutical Technology via Yahoo Finance· 2 weeks ago

     Although KRAS and its links to cancer were discovered decades ago, the characteristics of its protein structure were thought to make it “undruggable”....

2. • 

     Spectrum's (SPPI) NDA for NSCLC Candidate Gets CRL From FDA

     Zacks via Yahoo Finance· 2 years ago

     Spectrum Pharmaceuticals, Inc. SPPI announced that the company has received a Complete Response...

3. • 

     Pharma Stock Roundup: FDA and EMA Regulatory Updates for ABBV, LLY, SNY & MRK's Drugs

     Zacks via Yahoo Finance· 8 months ago

     This week, the European Commission granted marketing approval to AbbVie’s ABBV Tepkinly...

4. • 

     J&J's (JNJ) Rybrevant Combo Meets Primary Goal in NSCLC Study

     Zacks via Yahoo Finance· 8 months ago

     J&J (JNJ) meets the primary goal in the late-stage study of the combination therapy of Rybrevant and...

5. • 

     Kura Oncology, Inc. (NASDAQ:KURA) Q4 2022 Earnings Call Transcript

     Insider Monkey via Yahoo Finance· 1 year ago

     Kura Oncology, Inc. (NASDAQ:KURA) Q4 2022 Earnings Call Transcript February 23, 2023 Operator:...

6. • 

     Theseus (THRX) Up 57% in a Month on Strategic Restructuring Plan

     Zacks via Yahoo Finance· 6 months ago

     Theseus (THRX) gains 57% in a month after announcing plans to conduct a process exploring strategic...

7. • 

     Puma Biotech's (PBYI) Nerlynx Aids Top Line, Overdependence a Woe

     Zacks via Yahoo Finance· 2 years ago

     Puma Biotech (PBYI) has only one marketed product in its portfolio, Nerlynx, for HER-2 positive...

8. • 

     Merck Discontinues Two Keytruda Combo Therapy Trials In Prostate & Lung Cancer Settings

     Benzinga via Yahoo Finance· 1 year ago

     Merck & Co Inc (NYSE: MRK) is discontinuing the Phase 3 KEYNOTE-641 trial evaluating Keytruda...

9. • 

     Why Shares of Summit Therapeutics Slumped on Tuesday

     Motley Fool· 1 year ago

     Summit spent big on its collaboration and licensing agreement with Akeso to market ivonescimab, a bispecific antibody being tested in two phase 3 trials...

10. • The Hormel Institute scientist receives grant to study ways to prevent lung cancer progression

      Austin Daily Herald, Minn. via Yahoo News· 1 year ago

      Jan. 24—Luke Hoeppner, PhD, Associate Professor and leader of the Cancer Biology research section at The Hormel Institute, University of Minnesota, has received a grant from the Lung Cancer ...